Statistical Analysis
APPENDIX
Details of sample size calculations and analysis sets are included in the Appendix. Data were described descriptively using frequency and percentage for categorical variables and mean, standard deviation, median, minimum, and maximum for continuous variables. Efficacy analyses were performed separately for the PDGFRA D842V population and patients without PDGFRA D842Vmutations receiving avapritinib as fourth- or later-line treatment.*There were 6 patients from phase I and 53 patients from phase II in this dose group.